Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Latest Information Update: 08 Feb 2023
At a glance
- Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 08 Feb 2023 New trial record